Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTM-N2D (ANGELICA) Phase I in Advanced Cancers
NCT05302037Phase 1Recruiting
- Sponsor
- CytoMed Therapeutics
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic NKG2DL-targeting CAR-grafted gamma delta T cells in solid tumor (advanced stage) and hematologic malignancy (2 cohorts), sponsored by CytoMed Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 8 weeks and Treatment-Related Adverse Events at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
allogeneic NKG2DL-targeting CAR-grafted gamma delta T cells
03
Conditions
solid tumor (advanced stage)hematologic malignancy
Beyond the preview
Go deeper on NCT05302037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302037.